Pneumonia medicine Development Pipeline Review, 2017

1
Pneumonia Drug Development Pipeline Review, 2017
2
Summary

• This report provides an overview of the pipeline
  landscape for pneumonia disorders. The report
  provides comprehensive information on the
  therapeutics under development and key players
  involved in therapeutic development for Community
  Acquired Pneumonia, Hospital Acquired Pneumonia
  and Ventilator Associated Pneumonia and features
  dormant and discontinued projects.
• Community acquired pneumonia is pneumonia
  contracted by a person who has had little contact
  with the healthcare system, with common symptoms
  including cough, fever and shortness of breath.
  Risk factors include chronic lung disease,
  cigarette smoking, immune system problems and
  surgery.
• Hospital acquired pneumonia refers to any
  pneumonia contracted by a patient in a hospital
  at least 48-72 hours after being admitted. Signs
  and symptoms include malaise, fever, chills,
  rigor, cough, dyspnea, and chest pain, but in
  ventilated patients, pneumonia usually manifests
  as worsening oxygenation and increased tracheal
  secretions.

3
(No Transcript)
4

• Finally, ventilator associated pneumonia is
  pneumonia that occurs in people who are on
  mechanical ventilation breathing machines in
  hospitals. As such the disease typically affects
  critically ill patients and increases the risk of
  mortality. Signs and symptoms include fever or
  low body temperature, new purulent sputum and
  hypoxemia.
• The size of these pipelines ranges from 20
  products in community acquired pneumonia to 39 in
  hospital acquired pneumonia. Across all three of
  these indications bacterial targets such as DNA
  gyrase and ribosomal DNA are the most common
  targets, closely reflecting the current treatment
  landscape of these diseases.

5
Scope

• Which companies are the most active within the
  pipeline for pneumonia therapeutics?
• Which pharmaceutical approaches are the most
  prominent at each stage of the pipeline and
  within each indication?
• To what extent do universities and institutions
  play a role within this pipeline, compared to
  pharmaceutical companies?
• What are the most important RD milestones and
  data publications to have happened in the field
  of pneumonia?

6
Reasons to buy

• Understand the overall pipeline, with an
  at-a-glance overview of all products in
  therapeutic development for each indication
• Assess the products in development in granular
  detail, with an up-to-date overview of each
  individual pipeline program in each indication,
  and a comprehensive picture of recent updates and
  milestones for each
• Analyze the companies, institutions and
  universities currently operating in the pipeline,
  and the products being fielded by each of these
• Understand the composition of the pipeline in
  terms of molecule type, molecular target,
  mechanism of action and route of administration

7
Related Reports

• Global Bacterial Vaginosis Drug Market Analysis
  2011-2017 and Forecast 2018-2023
• Asia-Pacific Head Lice Infestation Drug Market by
  Manufacturers, Regions, Type and Application,
  Forecast to 2022
• Global Drugs for Malaria Market Analysis
  2011-2017 and Forecast 2018-2023
• Global Drug Addiction Partnering 2010 to 2017
• Global Dental Drug Market Analysis 2011-2017 and
  Forecast 2018-2023

8
Full Reports
Pneumonia Drug Development Pipeline Review, 2017
Contact us atBharat Book Bureau Tel 91 22
27810772 / 27810773 Email poonam_at_bharatbook.com O
ur Blog https//www.bharatbook.com/blog/ Twitter
https//twitter.com/researchbook Facebook
https//www.facebook.com/BharatBook3B LinkedIn
http//www.linkedin.com/company/bharat-book-bureau